505O Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C–mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase Ib CodeBreaK 101 study
Year: 2024
Type: article
Source: Annals of Oncology
Institutions: University of Milan, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, Institut Català d'Oncologia, Duran i Reynals Hospital, Hospital Universitario Ramón y Cajal, National Cancer Center Hospital East, University of Pisa, Hospital Clínic de Barcelona, Universitat Autònoma de Barcelona, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Duke University, Duke Medical Center, Duke Cancer Institute, University of Iowa Hospitals and Clinics, Thomas Jefferson University, Sidney Kimmel Cancer Center, Amgen (United Kingdom), Amgen (Switzerland), Amgen (United States), Aichi Cancer Center, Aichi Cancer Center Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, American Society of Clinical Oncology, Celgene, Array BioPharma, Taiho Pharmaceutical, Jazz Pharmaceuticals, Les Laboratories Pierre Fabre, Mirati Therapeutics, BeiGene, Incyte, Japan Society of Clinical Oncology, Advanced Accelerator Applications, Silverback Therapeutics, Seagen, Natera, Daiichi-Sankyo, Eisai, Astellas Pharma, European Society for Medical Oncology, Japanese Society of Medical Oncology, Sociedad Española de Oncología Médica, Servier, Novartis Farmacéutica, Yakult Honsha, PharmaMar, Menarini Group, Nordic Pharma Group, Genentech, Chugai Pharmaceutical, Eli Lilly Japan, Daiichi Sankyo Europe, Cilag
OpenAlex ID: W4402560898